Search bioRxiv⌕ Search

bioRxiv · 10.64898/2026.08.07.742730

Targeting glucocorticoid signalling in dendritic cells for glioblastoma treatment

Abstract

Glioblastoma (GBM) remains a devastating disease with few meaningful therapeutic advances over the past three decades. Dendritic cell (DC) vaccination is a promising immunotherapeutic strategy for GBM, but its efficacy is limited by the clinical use of dexamethasone to control cerebral oedema and associated symptoms. Here we show that steroid signalling is a central regulator of DC dysfunction in GBM. Through targeted metabolomics of primary GBM samples, we identified a steroid-rich tumour microenvironment in which dexamethasone is present at high levels. Across bulk and single-cell transcriptomic and epigenomic datasets, NR3C1 emerged as the dominant steroid receptor in GBM immune cells and was negatively associated with activated DC states. In patient-derived DCs, dexamethasone altered NR3C1 chromatin occupancy, induced broad transcriptional and chromatin remodelling, and suppressed co-stimulatory antigen-presentation and cytokine programmes. DC-specific deletion of Nr3c1 restricted syngeneic glioblastoma growth, enhanced DC activation, promoted cytotoxic CD8+ T cell responses and remodelled myeloid states in vivo. In GBM patient-derived DCs, pharmacological or non-viral CRISPR-mediated disruption of NR3C1 restored inflammatory, antigen presentation and T cell-stimulatory programmes, enhanced antigen-specific CD8+ T cell priming, and improved tumour lysate-loaded DC vaccination. Together, these findings identify glucocorticoid signalling as a key barrier to DC immunotherapy in GBM and establish NR3C1-targeted, steroid-resistant DCs as a potential therapeutic strategy.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Zhao, Q., Pramanik, J., Jabbar, A., Gui, Y., Chakraborty, S., Fysh, E., Ghosh, S., Puerto-Camacho, P., Santos, M. M., Al-deka, A., Pitoulias, M., Hussein, H., Ward, C. J., Gentsch, G., Homer, N. Z. M., Czech Nicholson, B., Roychoudhuri, R., Mair, R., Mahata, B.. 2026-08-12. Targeting glucocorticoid signalling in dendritic cells for glioblastoma treatment. https://doi.org/10.64898/2026.08.07.742730

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Nlrp6-dependent sentinel goblet cell functions dictate defensive responses during bacterial invasion of colonic crypts

The intestinal mucus layer serves as the primary physical barrier against microbial invasion, shielding the epithelium from luminal pathogens and inflammatory insults. This barrier is maintained by a heterogeneous population of goblet cells (GCs), which secrete regionally and organizationally distinct mucus layers. However, when this primary barrier is compromised, the burden of defense likely shifts to secondary mechanisms that remain incompletely defined. Therefore, we aimed to investigate the proposed role of microbe-sensing sentinel goblet cells (senGCs) as a secondary defensive mechanism that becomes critical when the primary mucus barrier fails, focusing on their capacity to mount localized secretory responses and preserve crypt sterility under challenge conditions. Using a GC specific Nlrp6 knockout model (Nlrp6{Delta}GC), we demonstrate that senGC deficiency leads to increased susceptibility to DSS induced colitis and Citrobacter rodentium infection, marked by exacerbated inflammation and enhanced crypt invasion respectively. Transcriptomic and immunolgical profiling revealed both common and sex-specific immune dysregulation, with especially female Nlrp6{Delta}GC mice exhibiting heightened mucosal pathogen burden, reduced Th17 expansion and increased CD8 T cell recruitment. The senGC-deficient mice also showed diminished baseline mucus secretion and accelerated GC loss during infection, suggesting a previously unrecognized mucus maintenance role for senGCs. Furthermore, infection induced expansion of Nlrp6 GCs in wild-type mice, enhancing MAMP-triggered mucus secretion, a response that is absent in Nlrp6{Delta}GC tissue. These findings confirm senGCs as an important regulator of epithelial protection by integrating GC-intrinsic microbial sensing with mucosal defense.

immunology↗

Exploratory positional differences in observed CDRH2 lineage-state transitions following HIV-1 germline-targeting vaccination

Background: Germline-targeting HIV-1 vaccination recruits VRC01-class B-cell precursors, but the positional patterns of observed longitudinal B-cell receptor lineage-state changes remain incompletely described. We compared CDRH2 profiles between homologous and heterologous boosting regimens using published IAVI G002 data. Methods: Participant-specific Week-8 lineages were prospectively matched to Week-24 observations. Germline-to-nongermline changes in sampled lineage-modal residues were evaluated at seven IGHV1-2*02 CDRH2 positions using participant-balanced, mean-centered profiles and exact participant-label permutation inference. Sampling-depth and sorting-probe sensitivity analyses assessed observability. A separate participant-held-out benchmark evaluated antibody-language-model representations for predicting observed Week-24 lineage detection. Results: The CDRH2 analysis included 332 lineages, 15 participants, 2,179 eligible lineage-position observations, and 241 observed state changes. The regional profile statistic was 0.027066 (exact p = 0.001709; six-region adjusted q = 0.010256), with descriptive differences at V-relative positions 51, 54, and 55. Most eligible longitudinal observations had one assessable cell per visit. In seven Group-1 participants, Week-24 dual-probe sampling recovered 181 baseline lineages with eOD-GT8 and 143 with Cg28v2, including 60 detected by both probes. In a separate cohort of 2,739 lineages from 17 participants, IgBERT and AbLang-2 representations did not improve participant-balanced average precision over a four-feature biological baseline. Conclusions: Observed CDRH2 lineage-modal-state profiles differed between regimens in this exploratory secondary analysis. Sparse sampling, potentially probe-related ascertainment, and absent linked functional validation preclude inference about mutation timing, functional improvement, or causal booster effects.

immunology↗

Multivalent mRNA tuberculosis vaccines protect against mycobacterial infection in zebrafish, mice and guinea pigs

Despite a century of BCG use, tuberculosis remains a leading cause of death from infectious diseases and more effective vaccines are urgently needed. Here we combined antigen discovery in zebrafish with mRNA vaccine technology to generate multivalent vaccine candidates, TUmRNA4, TUmRNA6 and TUmRNA9, encoding four, six, or nine Mycobacterium tuberculosis antigens, respectively. The vaccines were well tolerated, and induced robust antigen-specific cellular immune responses, including IFN{gamma} production and expansion of memory T-cell populations. In mice, TUmRNA4 and TUmRNA6 reduced pulmonary M. tuberculosis burden and lung pathology to levels comparable to BCG vaccination and TUmRNA6 enhanced BCG-mediated protection when used as a booster vaccine. In guinea pigs, TUmRNA9 reduced bacterial burden in the lungs, spleen, and lymph nodes and decreased pulmonary lesions. These findings demonstrate that protective antigens identified in zebrafish can be translated into effective multivalent mRNA vaccines and establish a framework for tuberculosis vaccine development across multiple preclinical models.

immunology↗